Mirikizumab for Crohn's Disease (VIVID-1 Trial)
Palo Alto (17 mi)Age: Any Age
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: Eli Lilly and Company
Pivotal Trial (Near Approval)
Prior Safety Data
Approved in 4 jurisdictions
Trial Summary
What is the purpose of this trial?This trial is testing whether mirikizumab is safe and effective for people with moderate to severe Crohn's disease. The drug works by reducing inflammation in the digestive tract, aiming to help those who may not respond well to other treatments. Mirikizumab has shown positive results in previous studies for Crohn's disease.
Eligibility Criteria
Treatment Details
3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: MirikizumabExperimental Treatment1 Intervention
Mirikizumab given intravenously (IV) and subcutaneously (SC).
Participants in the open-label adolescent addendum will be given mirikizumab IV and SC.
Group II: UstekinumabActive Control1 Intervention
Ustekinumab given IV and SC.
Group III: PlaceboPlacebo Group1 Intervention
Placebo given IV and SC.
Mirikizumab is already approved in European Union, United States, Canada, Japan for the following indications:
🇪🇺 Approved in European Union as Omvoh for:
- Moderately to severely active ulcerative colitis
🇺🇸 Approved in United States as Omvoh for:
- Moderately to severely active ulcerative colitis
🇨🇦 Approved in Canada as Omvoh for:
- Moderately to severely active ulcerative colitis
🇯🇵 Approved in Japan as Omvoh for:
- Moderately to severely active ulcerative colitis
Find a clinic near you
Research locations nearbySelect from list below to view details:
University of Washington School MedicineSeattle, WA
Emory UniversityAtlanta, GA
Medical Research Center of ConnecticutHamden, CT
Eagle Clinical ResearchChicago, IL
More Trial Locations
Loading ...
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor